top of page
Review Article

      Abstract    

        

HOME

A MINI-REVIEW ON RESPIRATORY DISEASES- CHRONIC OBSTRUCTIVE PULMONARY DISEASE, TUBERCULOSIS, AND PNEUMONIA- A GLOBAL HEALTH ISSUE

 

Princal Patel

​

ABSTRACT:

The lungs are the crucial organ that can be infected or injured by airborne particles. Respiratory disorders are the main cause of mortality and morbidity worldwide. COPD affects around 65 million people globally and kills three million people annually, the world's third greatest reason for mortality. Pneumonia kills millions of citizens each year and is the top cause of mortality in kids under the age of five. Every year, about Ten million people contract tuberculosis (TB), and more than one million people die from it, ranking it as the most prevalent fatal infectious illness. "Prevention, control, and cure" of these disorders, as well as improvement of lung diseases, must be primary concerns in global health judgment. The current article will, without hesitation, raise global understanding about the major respiratory illnesses and spur actions among all stakeholders. This article presents a comprehensive study and highlights the recent changes in respiratory diseases such as Chronic Obstructive Pulmonary Disease, Tuberculosis, and Pneumonia considering the extent of a global problem, Epidemiology, Pathology and pathogenesis, preventive strategies, and treatment.

 

KEYWORDS: Respiratory Disease; COPD; Tuberculosis; Pneumonia

​

REFERENCES:​

  1. [1]. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1459–1544.

  2. [2]. World Health Organization. Global surveillance, prevention and control of chronic respiratory diseases. A comprehensive approach. Geneva, WHO, 2007.

  3. [3]. Burney PG, Patel J, Newson R, Minelli C, Naghavi M. Global and regional trends in COPD mortality, 1990- 2010. Eur Respir J 2015; 45: 1239–1247.

  4. [4]. Global Asthma Report. Auckland, Global Asthma Network, 2014.

  5. [5]. Pearce N, Ait-Khaled N, Beasley R. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2007; 62: 758–766.

  6. [6]. Pneumonia: The forgotten killer of children. Geneva, The United Nations Children’s Fund (UNICEF)/ World Health Organization (WHO), 2006.

  7. [7]. Global Tuberculosis Report 2016. Geneva, World Health Organization, 2016.

  8. [8]. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87–108.

  9. [9]. GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1603–1658.

  10. [10]. B.R. Celli, M. Decramer, J.A. Wedzicha. An official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease Am J Respir Crit Care Med, 191 (7) (2015), pp. e4-e27

  11. [11]. D.A. Seamark, S.D. Blake, C.J. Seamark, D.M. Halpin Living with severe chronic obstructive pulmonary disease (COPD): Perceptions of patients and their carers. An interpretative phenomenological analysis Palliat Med, 18 (7) (2004), pp. 619-625

  12. [12]. W.Q. Gan, S.F. Man, A. Senthilselvan, D.D. Sin Association between chronic obstructive pulmonary disease and systemic inflammation: A systematic review and a meta-analysis Thorax, 59 (7) (2004), pp. 574-580

  13. [13]. K. Ito, T. Colley, N. Mercado Geroprotectors as a novel therapeutic strategy for COPD, an accelerating aging disease Int J Chron Obstruct Pulmon Dis, 7 (2012), pp. 641-652

  14. [14]. R. Varraso, T.T. Fung, R.G. Barr, F.B. Hu, W. Willett, C.A. Camargo Jr., Prospective study of dietary patterns and chronic obstructive pulmonary disease among US women, Am J Clin Nutr, 86 (2) (2007), pp. 488-495

  15. [15]. C. Hanson, E. Lyden, S. Rennard. The relationship between dietary fiber intake and lung function in the National Health and Nutrition Examination Surveys, Ann Am Thorac Soc, 13 (5) (2016), pp. 643-650.

  16. [16]. D. Handu, L. Moloney, T. Wolfram, P. Ziegler, A. Acosta, A. Steiber, Academy of Nutrition and Dietetics Methodology for conducting systematic reviews for the Evidence Analysis Library, J Acad Nutr Diet, 116 (2) (2016), pp. 311-318.

  17. [17]. Academy of Nutrition and Dietetics, Nutrition Terminology Reference Manual (eNCPT): Dietetics language for nutrition care, http://ncpt.webauthor.com, Accessed 4th Sep 2019.

  18. [18]. Montes de Oca M, Lopez Varela MV, Acuna A. ALAT-2014 chronic obstructive pulmonary disease (COPD) clinical practice guidelines: questions and answers. Arch Bronconeumol 2015; 51: 403–416.

  19. [19]. Criner GJ, Bourbeau J, Diekemper RL. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest 2015; 147: 894–942.

  20. [20]. Spruit MA, Singh SJ, Garvey C. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013; 188: e13–e64.

  21. [21]. Asher I, Pearce N. Global burden of asthma among children. Int J Tuberc Lung Dis 2014; 18: 1269–1278.

  22. [22]. Chadha VK. Progress towards Millennium Development Goals for TB control in seven Asian countries. Indian J Tuberc. 2009;56:30–43.

  23. [23]. Kaye K, Frieden TR. Tuberculosis control: the relevance of classic principles in an era of acquired immunodeficiency syndrome and multidrug resistance. Epidemiol Rev. 1996;18:52–63.

  24. [24]. World Health Organization . Global tuberculosis control 2009: epidemiology, strategy, financing: WHO report 2009. Geneva: World Health Organization; 2009. p. 303. (WHO/HTM/TB/2009.411).

  25. [25]. Dye C. Global epidemiology of tuberculosis. Lancet. 2006;367:938–40.

  26. [26]. Cantwell MF, Mckenna MT, McCray E, Onorato IM. Tuberculosis and race/ethnicity in United States: impact of socioeconomic status. Am J Respir Crit Care Med. 1998;157:1016–20.

  27. [27]. Davies PD. Tuberculosis: the global epidemic. J Ind Med Assoc. 2000;98:100–02.

  28. [28]. Luby SP, Brooks WA, Zaman K, Hossain S, Ahmed T. Infectious diseases and vaccine sciences: strategic directions. J Health Popul Nutr. 2008;26:295–310.

  29. [29]. TB CARE I. International Standards for Tuberculosis Care, Edition 3. TB CARE I, The Hague, 2014.

  30. [30]. Moodley R, Godec TR, Team ST. Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials. Eur Respir Rev 2016; 25: 29–35.

  31. [31]. Jose  RJ, Periselneris JN, Brown JS. Community-acquired pneu- monia. Curr Opin Pulm Med 2015; 21: 212e8.

  32. [32]. Gubbins PO, Li C. The influence of influenza and pneumo- coccal vaccines on community-acquired pneumonia (CAP) outcomes among elderly patients. Curr Infect Dis Rep 2015; 17: 49.

  33. [33]. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 2006; 19: 571e82.

  34. [34]. Biteker FS, Yõldõrõm B. Biomarkers in community-acquired pneumonia. J Infect 2015.

  35. [35]. Aliberti S, Cilloniz C, Chalmers JD. Multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia: a European perspective. Thorax 2013; 68: 997–999.

  36. [36]. Giamarellou H, Poulakou G Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs 2009; 69: 1879–1901.

  37. [37]. The Center for Disease Dynamics, Economics and Policy. The State of the World's Antibiotics 2015. Washington, The Center for Disease Dynamics, Economics and Policy (CDDEP), 2015. 

  38. [38]. Chahwakilian P, Huttner B, Schlemmer B. Impact of the French campaign to reduce inappropriate ambulatory antibiotic use on the prescription and consultation rates for respiratory tract infections. J Antimicrob Chemother 2011; 66: 2872–2879.

  39. [39]. McDonagh M, Peterson K, Winthrop K. Improving antibiotic prescribing for uncomplicated acute respiratory tract infections [Internet]. AHRQ Comparative Effectiveness Reviews 2016; 163: 5(16)-EHC033-EF.

  40. [40]. National Action Plan for Combating Antibiotic-Resistant Bacteria. Washington, The White House, 2015. 

  41. [41]. U.S. Food & Drug Administration (FDA). News Release: New FDA task force will support innovation in antibacterial drug development. Silver Spring, MD, U.S. Food & Drug Administration (FDA), 24 September 2012

  42. [42]. van der Eerden MM, Vlaspolder F, de Graaff CS. Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2005; 24: 241–249.

 To cite this article:

Patel P. A mini-review on respiratory diseases- chronic obstructive pulmonary disease, tuberculosis, and pneumonia- a global health issue. Int. J. Med. Lab. Res. 2022; 7,3.  http://doi.org/10.35503/IJMLR.2022.7303.

bottom of page